論文 - 詳細
| RRC ID | 63288 |
|---|---|
| 著者 | Yamaguchi H, On J, Morita T, Suzuki T, Okada Y, Ono J, Evdokiou A. |
| タイトル | Combination of Near-Infrared Photoimmunotherapy Using Trastuzumab and Small Protein Mimetic for HER2-Positive Breast Cancer. |
| ジャーナル | Int J Mol Sci |
| Abstract |
Near-infrared photoimmunotherapy (NIR-PIT) is a promising cancer therapy based on a monoclonal antibody conjugated to a photosensitizer (IR700Dye) that is activated by near-infrared light irradiation. We previously reported on the use of NIR-PIT with a small protein mimetic, the Affibody molecule (6-7 kDa), instead of a monoclonal antibody. In this study, we investigated a combination of NIR-PIT for HER2-positive breast cancer cells (SK-BR3, MDA-MB361, and JIMT1) with HER2 Affibody-IR700Dye conjugate and trastuzumab-IR700Dye conjugate. HER2 Affibody and trastuzumab target different epitopes of the HER2 protein and do not compete. In vitro, the combination of NIR-PIT using both HER2 Affibody-IR700Dye conjugate and trastuzumab-IR700Dye conjugate induced necrotic cell death of HER2-positive breast cancer cells without damage to HER2-negative breast cancer cells (MCF7). It was more efficient than NIR-PIT using either the HER2 Affibody-IR700Dye conjugate alone or the trastuzumab-IR700Dye conjugate alone. Additionally, this combination of NIR-PIT was significantly effective against HER2 low-expressing cancer cells, trastuzumab-resistant cells (JIMT1), and brain metastatic cells of breast cancer (MDA-MB361). Furthermore, in vivo imaging exhibited the strong fluorescence intensity of both HER2 Affibody-IR700Dye conjugates and trastuzumab-Alexa488 conjugates in HER2-positive tumor, indicating that both HER2 Affibody and trastuzumab specifically bind to HER2-positive tumors without competing with each other. In conclusion, the combination of NIR-PIT using both HER2 Affibody and trastuzumab expands the targeting scope of NIR-PIT for HER2-positive breast cancer. |
| 巻・号 | 22(22) |
| 公開日 | 2021-11-11 |
| DOI | 10.3390/ijms222212213 |
| PII | ijms222212213 |
| PMID | 34830099 |
| PMC | PMC8618566 |
| MeSH | Biomimetic Materials / pharmacology* Breast Neoplasms / metabolism Breast Neoplasms / therapy* Female Fluorescent Dyes / pharmacology Humans Immunotherapy* MCF-7 Cells Phototherapy* Receptor, ErbB-2 / antagonists & inhibitors* Receptor, ErbB-2 / metabolism Trastuzumab / pharmacology* |
| IF | 2.504 |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | X(Twitter) |
| 各媒体での言及数の合計 | 1 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | MCF7(RCB1904) |